Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer's DiseaseGlobeNewsWire • 01/15/25
New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer's Disease PatientsGlobeNewsWire • 01/13/25
Here's Why 'Trend' Investors Would Love Betting on Anavex Life Sciences (AVXL)Zacks Investment Research • 01/07/25
Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/06/25
Are Medical Stocks Lagging Anavex Life Sciences (AVXL) This Year?Zacks Investment Research • 12/31/24
All You Need to Know About Anavex Life Sciences (AVXL) Rating Upgrade to BuyZacks Investment Research • 12/30/24
Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business UpdateGlobeNewsWire • 12/23/24
Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer's DiseaseGlobeNewsWire • 12/23/24
Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024GlobeNewsWire • 12/16/24
Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer's Disease Data at J.P. Morgan 2025 Healthcare ConferenceGlobeNewsWire • 12/09/24
Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024GlobeNewsWire • 12/02/24
Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer's Disease to EMAGlobeNewsWire • 11/26/24
Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer's Disease JournalGlobeNewsWire • 11/25/24
Anavex Life Sciences: Weighing The Pros And Cons Of A Possible EU Approval ScenarioSeeking Alpha • 11/06/24
Anavex's Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer's Trial: Data Presented at CTAD Conference 2024GlobeNewsWire • 10/31/24
Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of SchizophreniaGlobeNewsWire • 10/17/24
Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024GlobeNewsWire • 09/03/24